SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice

• Published in: Vaccines (Basel) Vol. 11; no. 4; p. 808
• Main Authors: Volosnikova, Ekaterina A., Merkuleva, Iuliia A., Esina, Tatiana I., Shcherbakov, Dmitry N., Borgoyakova, Mariya B., Isaeva, Anastasiya A., Nesmeyanova, Valentina S., Volkova, Natalia V., Belenkaya, Svetlana V., Zaykovskaya, Anna V., Pyankov, Oleg V., Starostina, Ekaterina V., Zadorozhny, Alexey M., Zaitsev, Boris N., Karpenko, Larisa I., Ilyichev, Alexander A., Danilenko, Elena D.
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.04.2023; MDPI
• Subjects: adjuvant; Adjuvants; Aluminum; Animals; Antibodies; Antibody-drug conjugates; Antigens; CD4 antigen; CD8 antigen; Cloning; Comparative analysis; Coronaviruses; COVID-19; COVID-19 vaccines; Dosage and administration; Double-stranded RNA; Immune response; Immune response (humoral); Immune system; Immunization; Immunogenicity; Immunoglobulin G; Laboratory animals; Lymphocytes; Lymphocytes T; Nanoparticles; Neutralizing; Polyamines; Proteins; RBD; receptor-binding domain; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Spermidine; Spike protein; Testing; Vaccines; Vectors (Biology); Viral diseases; Yeast; Russia; United States > US; Germany; COVID-19; SARS-CoV-2; RBD; adjuvant; receptor-binding domain

Despite the rapid development and approval of several COVID vaccines based on the full-length spike protein, there is a need for safe, potent, and high-volume vaccines. Considering the predominance of the production of neutralizing antibodies targeting the receptor-binding domain (RBD) of S-protein...